<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870037</url>
  </required_header>
  <id_info>
    <org_study_id>ION 03-OAB</org_study_id>
    <nct_id>NCT01870037</nct_id>
  </id_info>
  <brief_title>Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer</brief_title>
  <acronym>OAB</acronym>
  <official_title>Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ion Channel Innovations</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of a single treatment of&#xD;
      hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections.&#xD;
      Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in&#xD;
      females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration&#xD;
      will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 double-blind, placebo-controlled study assessing the safety and activity of&#xD;
      2 escalating doses of hMaxi-K gene transfer by direct injection into the bladder wall in&#xD;
      female participants with OAB/DO.&#xD;
&#xD;
      The safety parameters to be monitored include: adverse events, clinical laboratory tests,&#xD;
      electrocardiograms, and physical examinations.&#xD;
&#xD;
      The secondary objective is to evaluate the efficacy of multiple intramuscular injections of&#xD;
      hMaxi-K compared to the control group. Efficacy parameters that will be evaluated are: number&#xD;
      of micturitions per 24 hours, volume per micturition, incontinence episodes, pad weight&#xD;
      measurement of accidental bladder leaks, uninhibited contractions during cystoscopy and other&#xD;
      cystoscopic evaluations, and general and bladder-specific quality of life assessments (Kings&#xD;
      Health Questionnaire, SF-12 Health Survey, and International Consultation on Incontinence&#xD;
      Questionnaire [ICIQ-SF]).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">February 17, 2018</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>sequential, dose escalation</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant clinical laboratory test value during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant clinical laboratory test value during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant electrocardiogram finding during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant electrocardiogram finding during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant physical examination finding during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant physical examination finding during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the number of micturitions per day</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the volume of micturitions</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in incontinence episodes</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pad weight</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in uninhibited contractions during cystoscopy</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the participant rating of the Kings Health Questionnaire (KHQ) score</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the International Consultation on Incontinence Questionnaire-Short Form score</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Short Form-12 (SF-12) score</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Placebo (PBS-20% sucrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hMaxi-K 16000 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hMaxi-K 24000 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PBS-20% sucrose)</intervention_name>
    <arm_group_label>Placebo (PBS-20% sucrose)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMaxi-K</intervention_name>
    <description>Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)</description>
    <arm_group_label>hMaxi-K 16000 µg</arm_group_label>
    <arm_group_label>hMaxi-K 24000 µg</arm_group_label>
    <other_name>URO-902</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy women of ≥18 years of age and non-childbearing potential&#xD;
&#xD;
          2. Symptoms of overactive bladder for ≥6 months including at least one of the following:&#xD;
&#xD;
               1. Frequent micturition ≥8 times per 24 hours&#xD;
&#xD;
               2. Urinary urgency or nocturia&#xD;
&#xD;
               3. Urge urinary incontinence five or more incontinence episodes per week&#xD;
&#xD;
          3. Detrusor overactivity with ≥1 uncontrolled phasic contraction(s) of the detrusor of at&#xD;
             least 5 centimeters/H20 pressure documented on cystometry at Screening Visit 1A&#xD;
&#xD;
          4. Residual urine volume of ≤200 milliliters (ml)&#xD;
&#xD;
          5. Non-response or poor tolerance to previous treatment for symptoms of OAB/urinary&#xD;
             incontinence and do not wish to continue these treatments&#xD;
&#xD;
          6. Have screening laboratory values and electrocardiogram that are within the normal&#xD;
             range&#xD;
&#xD;
          7. Able to understand study requirements (i.e., literate in English), give written&#xD;
             informed consent, and comply with all study procedures and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A woman with a positive serum (HCG) pregnancy test or who is lactating&#xD;
&#xD;
          -  History of three or more culture-documented recurrent urinary tract infections per&#xD;
             year&#xD;
&#xD;
          -  Current history or previous diagnosis of painful bladder syndrome (interstitial&#xD;
             cystitis) with pain in the region of the pelvis, perineum, or lower abdomen relieved&#xD;
             by voiding&#xD;
&#xD;
          -  Current history of neurological bladder dysfunction&#xD;
&#xD;
          -  A life expectancy of less than 12 months&#xD;
&#xD;
          -  Current history of Grade 2 or greater cystocele&#xD;
&#xD;
          -  An indwelling urethral catheter or need for clean intermittent self-catheterization&#xD;
&#xD;
          -  Recent heart attack&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Latex allergy&#xD;
&#xD;
          -  Stress urinary incontinence as determined by observation of the participant coughing&#xD;
             while standing with a full bladder and/or response of 2 or 3 on the following Stress&#xD;
             Urinary Incontinence question: Do you experience leakage when laughing, coughing,&#xD;
             lifting heavy objects or other types of discreet, moderately intense activities?&#xD;
             0=NONE: No leakage. 1=MILD: Minimal leakage on rare occasions during these types of&#xD;
             activities; easily tolerated; do not use pads for this. 2=MODERATE: Enough leakage&#xD;
             that it requires occasional use of pads and may interfere with usual activity and&#xD;
             tasks. 3=SEVERE: Extreme leakage and discomfort that stops all activity and tasks and&#xD;
             requires the use of pads on all occasions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>OAB</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual participant data will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01870037/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01870037/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01870037/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

